Evidence map›Paper›PMID 28157234›Full record

ArticleScientific reports2017

The citrus flavanone naringenin impairs dengue virus replication in human cells.

Sandra Frabasile, Andrea Cristine Koishi, Diogo Kuczera, Guilherme Ferreira Silveira, Waldiceu Aparecido Verri, Claudia Nunes Duarte Dos Santos, Juliano Bordignon

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 137 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Antiviral Potential ofInternational journal of molecular sciences · 2024
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
    Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sandra FrabasileSección Virologia, Facultad de Ciencias, Universidad de La República, 11400, Montevideo, Uruguay.
Andrea Cristine KoishiLaboratório de Virologia Molecular, Instituto Carlos Chagas, ICC/FIOCRUZ/PR, Curitiba, Paraná, Brazil.
Diogo KuczeraLaboratório de Virologia Molecular, Instituto Carlos Chagas, ICC/FIOCRUZ/PR, Curitiba, Paraná, Brazil.
Guilherme Ferreira SilveiraLaboratório de Virologia Molecular, Instituto Carlos Chagas, ICC/FIOCRUZ/PR, Curitiba, Paraná, Brazil.
Waldiceu Aparecido VerriDepartamento de Ciências Patológicas, Centro de Ciências Biológicas, Universidade Estadual de Londrina, Paraná, Brazil.
Claudia Nunes Duarte Dos SantosSección Virologia, Facultad de Ciencias, Universidad de La República, 11400, Montevideo, Uruguay.
Juliano BordignonSección Virologia, Facultad de Ciencias, Universidad de La República, 11400, Montevideo, Uruguay.
Fundação Carlos Chagas · BRUniversidad de la República de Uruguay · UYUniversidade Estadual de Londrina · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dengue is one of the most significant health problems in tropical and sub-tropical regions throughout the world. Nearly 390 million cases are reported each year. Although a vaccine was recently approved in certain countries, an anti-dengue virus drug is still needed. Fruits and vegetables may be sources of compounds with medicinal properties, such as flavonoids. This study demonstrates the anti-dengue virus activity of the citrus flavanone naringenin, a class of flavonoid. Naringenin prevented infection with four dengue virus serotypes in Huh7.5 cells. Additionally, experiments employing subgenomic RepDV-1 and RepDV-3 replicon systems confirmed the ability of naringenin to inhibit dengue virus replication. Antiviral activity was observed even when naringenin was used to treat Huh7.5 cells 24 h after dengue virus exposure. Finally, naringenin anti-dengue virus activity was demonstrated in primary human monocytes infected with dengue virus sertoype-4, supporting the potential use of naringenin to control dengue virus replication. In conclusion, naringenin is a suitable candidate molecule for the development of specific dengue virus treatments.

Indexed as

Virus ReplicationCell LineDengue VirusFlavanonesHumansFlavanonesnaringenin

Identifiers

PMID28157234
PMCPMC5291091
OpenAlexW2585326482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.